Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

Author: Howard, JF, et al. Overview Provided by Nicolas Silvestri, MD

Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

Author: Strober J, et al. Overview Provided by Nicolas Silvestri, MD

Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results

Author: Nicolle M, et al. Overview Provided by Nicolas Silvestri, MD

Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

Author: Habib AA, et al Overview Provided by Nicolas Silvestri, MD